A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMORS
The purpose of this part of the research study is to evaluate how CGT9486 plus sunitinib affects GIST compared to just treatment with sunitinib alone.
DiagnosisGastrointestinal Stromal Tumors that cannot be surgically removed, have come back after initial treatment, or have spread to other parts of the body
Must have locally advanced, metastatic, and/or unresectable GIST, and have received prior therapy with imatinib.
CGT9486+SUNITINIB VS SUNITINIB
For more information visit Clinicaltrials.gov